

Provided by:



Thoracic Oncology Tumor Board 2019-2021

Thoracic Oncology Tumor Board 2019-2021

January 29, 2021

8:00 AM - 9:00 AM

PCAM South 12-122

Target Audience

This program has been designed for Internal Medicine - Hematology, Interventional Radiology And Diagnostic Radiology, Pathology - Clinical, Internal Medicine - Pulmonary Disease, Radiation Oncology, Thoracic And Cardiac Surgery, Medical Genetics And Genomics - Molecular Genetic Pathology, Pathology - Cytopathology, Pathology - Hematopathology, Pathology - Pathology-Medical Microbiology, Pathology - Pathology-Molecular Genetic

Series Educational Objectives

After participating in this regularly scheduled series, participants should be able to:

- 1 Delineate institutional and national pathways/guidelines in the management of thoracic malignancy
- 2 Facilitate multidisciplinary care and discussion to improve outcomes and quality of life
- 3 Capitalize on the critical role of radiology and pathology in the multidisciplinary management of thoracic cancer
- 4 Increase awareness clinical trials at the ACC and throughout the nation and to enhance enrollment in clinical trials

Accreditation

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physicians: Penn Medicine designates this live activity for a maximum of **1.00 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: This activity is for **1.00** contact hours.

Pharmacists: This activity is not approved for pharmacy contact hours

PAs: AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit™* from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of **1.00** Category 1 credits for completing this activity.

Approved for (PSRM) patient safety/risk management designation

Acknowledgement of Commercial Support*

None

For more information, please contact
Megan Roy
(215) 360-0586
megan.roy@penntmedicine.upenn.edu

Check your transcript online at <https://upenn.cloud-cme.com>

Disclosure of Relevant Financial Relationships and Unapproved Uses of Products

It is policy at Penn Medicine Office of Continuing Medical and Interprofessional Education for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships that they have with any commercial interest that provide products or services that may be relevant to the content of this continuing education activity. For this purpose, we consider relationships of the person involved to include financial relationships of a spouse or partner.

The intent of this policy is to ensure that Penn CME/CE certified activities promote quality and safety, are effective in improving medical practice, are based on valid content, and are independent of control from commercial interests and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information was found to contain relationships that created a conflict of interest relevant to the topic of their presentation. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations.

The staff in the Office of Continuing Medical and Interprofessional Education (CME and IPCE), have disclosed that they have no relevant financial relationships with any commercial interests related to the content of this educational activity. Any peer reviewer with a potential conflict of interest will recuse themselves from the peer review process.

Name of individual	Individual's role in activity	Name of commercial interest/Nature of relationship
Aditi Singh, MD	Activity Administrator	Nothing to disclose
John Kucharczuk, MD	Activity Owner	Nothing to disclose
Corey Langer, MD	Co-Director	Grants/Research Support Recipient-Merck and Company, Inc.-Oncology Grants/Research Support Recipient-Takeda Pharmaceuticals, Inc.-Oncology Grants/Research Support Recipient-AstraZeneca-Oncology Grants/Research Support Recipient-Bristol-Myers Squibb-Oncology Grants/Research Support Recipient-Inovio-Oncology Grants/Research Support Recipient-Trizell-Oncology Advisor or Review Panel Member-AstraZeneca-Oncology Advisor or Review Panel Member-Takeda Pharmaceuticals, Inc.-Oncology Advisor or Review Panel Member-Hospira-Oncology Advisor or Review Panel Member-Gilead-Oncology Grants/Research Support Recipient-Guardant Consultant-Boehringer Ingelheim Vetmedica GmbH-Oncology Independent Contractor-Eli Lilly and Company-DSMC Independent Contractor-Amgen-DSMC
Megan Roy, RN	Co-Director, Faculty	Nothing to disclose
Charu Aggarwal, MD	Other Planning Committee Member	Consultant-Bristol-Myers Squibb Aventis Consultant-AstraZeneca Consultant-Eli Lilly and Company Consultant-Merck and

		Company, Inc. Consultant-Genentech, Inc.
Joshua Bauml, MD	Other Planning Committee Member	Grants/Research Support Recipient-Merck and Company, Inc.- Oncology Grants/Research Support Recipient-Incyte-Oncology Grants/Research Support Recipient-Carevive Systems Grants/Research Support Recipient-Novartis AG-Oncology Grants/Research Support Recipient-Bayer Corporation-Oncology Grants/Research Support Recipient-Johnson and Johnson-Oncology Grants/Research Support Recipient-AstraZeneca-Oncology Grants/Research Support Recipient-Takeda Pharmaceuticals, Inc.-Oncology Grants/Research Support Recipient-Amgen-Oncology Consultant-Bristol-Myers Squibb-Oncology Consultant-AstraZeneca-Oncology Consultant-Celgene-Oncology Consultant-Merck and Company, Inc.-Oncology Consultant-Johnson and Johnson-Oncology Consultant-Genentech, Inc.-Oncology Consultant-Guardant Health-Oncology Consultant-Boehringer Ingelheim Vetmedica GmbH-Oncology Consultant-Takeda Pharmaceuticals, Inc.-Oncology Consultant-Regeneron-Oncology Consultant-Ayala-Oncology Consultant-Inivata-Oncology Consultant-Agilent-Oncology
Abigail T. Berman, MD, MSCE	Other Planning Committee Member	Consultant-AstraZeneca Grants/Research Support Recipient-Merck and Company, Inc. Consultant-IMX Speakers' Bureau-Varian
Christine Ciunci, MD	Other Planning Committee Member	Grants/Research Support Recipient-Bristol-Myers Squibb Grants/Research Support Recipient-Merck and Company, Inc. Speaker/Honorarium-Imedex Grants/Research Support Recipient-Celgene Grants/Research Support Recipient-MacroGenics
Roger Cohen, MD	Other Planning Committee Member	Nothing to disclose
David Dibardino, MD	Other Planning Committee Member	Consultant-Boston Scientific Corporation
Andrew Haas, MD	Other Planning Committee Member	Consultant-Serpex Medical -bronchoscopy device development Data Safety Monitoring Board -Novocure -oncology therapy device
Doraid Jarrar, MD	Other Planning Committee Member	Nothing to disclose
Cengel Keith, MD, PhD	Other Planning Committee Member	Nothing to disclose
John Kosteva, MD	Other Planning Committee Member	Nothing to disclose

William Levin, MD	Other Planning Committee Member	Nothing to disclose
Leslie Litzky, MD	Other Planning Committee Member	Nothing to disclose
Kevin Ma, MD	Other Planning Committee Member	Nothing to disclose
Melina Marmarelis, MD	Other Planning Committee Member	Stock Shareholder (excluding mutual funds)-Merck and Company, Inc.-Lung cancer therapy Grants/Research Support Recipient-Genentech, Inc. Grants/Research Support Recipient-Eli Lilly and Company Grants/Research Support Recipient-Trizell Stock Shareholder (excluding mutual funds)-Johnson and Johnson-Lung cancer therapy Stock Shareholder (excluding mutual funds)-Novartis AG-Lung cancer therapy Stock Shareholder (excluding mutual funds)-Pfizer, Inc.-Lung cancer therapy Consultant-Novocure-Mesothelioma tumor treating fields Consultant-Boehringer Ingelheim Vetmedica GmbH Grants/Research Support Recipient-AstraZeneca-Research grant
Taine Pechet, MD	Other Planning Committee Member	Nothing to disclose
Sunil Singhal, MD	Other Planning Committee Member	Nothing to disclose
Samuel Swisher-McClure, MD	Other Planning Committee Member	Nothing to disclose

Relevant financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected